Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.

54.80 1.74 −3.08%
Market cap
$8.6B
P/E
0.0×
Fwd P/E
55.7×
Dividend yield
0.36%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.43 2.08 1.59 2.62
P/FCF ratio
347.32 105.01 72.24 77.21
P/Operating CF
(148.55) 31.12 77.21 (118.42)
P/B ratio
2.01 2.89 2.23 3.82
EV/Sales
1.93 2.54 2.03 3.09
EV/EBITDA
23.82 30.23 25.60 54.16
EV/FCF
468.13 128.07 92.45 91.03
Current Ratio
1.85 1.73 1.55 1.85
Net Debt/EBITDA
439.85 11.68 22.45 (224.64)
Debt/Equity
0.82 0.76 0.68 0.76
Earnings Yield
(0.49%) (0.32%) (0.66%) (1.16%)
Free Cash Flow Yield
0.29% 0.95% 1.38% 1.30%
Free Cash Flow per Share
(0.36) 1.37 0.31 (0.70)
Book value per Share
16.14 16.29 16.21 15.76
Free Cash Flow
(54.10) 207.20 47.00 (106.20)
EV/EBIT
103.87 127.88 150.97 0.00
Other line items

Show all line items

Columns are period end dates